6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

450, 5th Street

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of July, 2006

Daiichi Sankyo Company, Limited

(Translation of registrant’s name into English)

5-1, Nihonbashi 3-chome

Chuo-ku, Tokyo 103-8426

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  þ            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  ¨            No  þ

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  ¨            No  þ

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨            No  þ

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DAIICHI SANKYO COMPANY, LIMITED
DATE: July 14, 2006	By:	/S/ Takashi Shoda
	Name:	Takashi Shoda
	Title:	President and Representative Director

EXHIBIT INDEX

Exhibit Number		Description of Exhibit
99.1	—	Press Release: “Sankyo’s European Subsidiaries’ Names Change”
99.2	—	Press Release: “Sales Agreement for EVISTA® Reached in Europe”

EX-99.1

Exhibit 99.1

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Takashi Shoda, President and Representative Director

(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,

Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.co.jp/

Sankyo’s European Subsidiaries’ Names Change

Tokyo, July 14, 2006 – DAIICHI SANKYO COMPANY, LIMITED has announced that the corporate names of the Group companies under the umbrella of Sankyo Pharma GmbH (hereafter, SPG), which is the European subsidiary of Sankyo Co., Ltd., were changed on July 1, 2006 in anticipation of the complete management integration of Daiichi Pharmaceutical and Sankyo in April 2007.

SPG has become DAIICHI SANKYO EUROPE GmbH (hereafter, DSE), and together with its eleven Group subsidiaries, will focus mainly on the manufacture, sales, and development of pharmaceuticals in Europe. Based in Europe, DSE will proactively press forward with the development of global business along with DAIICHI SANKYO, INC. which was newly formed as a result of an integration in the US in April of this year.

DAIICHI SANKYO EUROPE GmbH Group Organization

Capital: 16 million euro

Officers: Reinhard Bauer (CEO), Max Schoener (CFO)

EX-99.2

Exhibit 99.2

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Takashi Shoda, President and Representative Director

(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,

Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.co.jp/

Sales Agreement for EVISTA® Reached in Europe

Tokyo, July 14, 2006 – DAIICHI SANKYO EUROPE GmbH (Headquarters: Munich, Germany), the European subsidiary of DAIICHI SANKYO’s wholly-owned subsidiary, Sankyo Co., Ltd. (President: Yasuhiro Ikegami; hereafter Sankyo), and Eli Lilly and Company have signed a marketing and distribution agreement for EVISTA® (raloxifene), an osteoporosis drug, in certain European countries (Germany, Italy, Belgium, Netherlands, Austria, and Switzerland).

EVISTA®, which was developed by Eli Lilly and Company, is a selective estrogen receptor modulator that inhibits bone resorption. In Europe, it is indicated for the treatment and prevention of osteoporosis in post-menopausal women.

Note: Sankyo’s European subsidiary, Sankyo Pharma GmbH, changed its name to DAIICHI SANKYO EUROPE GmbH.